Not approved (research only)Senolytic peptideLongevity research
FOXO4-DRI
FOXO4-DRI is a modified peptide designed to disrupt FOXO4-p53 binding and clear senescent cells in mouse studies.
What is FOXO4-DRI?
FOXO4-DRI is a modified peptide designed to disrupt FOXO4-p53 binding and clear senescent cells in mouse studies. FOXO4-DRI is not approved by the FDA for any use; products sold under this name are labeled for research use only, not for human consumption.
Key takeaways
- FOXO4-DRI is not approved by the FDA for any use; products sold under this name are labeled for research use only, not for human consumption.
- PubMed indexes 19 papers on FOXO4-DRI (0 tagged as clinical trials) as of October 19, 2026.
- 13 vendors in our directory listed FOXO4-DRI in their public catalog on October 19, 2026.
Regulatory & access status
FOXO4-DRI is not approved by the FDA for any use; products sold under this name are labeled for research use only, not for human consumption.
Sellers that market unapproved peptides for human use can receive FDA warning letters; our vendor directory links any letter we found on fda.gov.
How much research exists on FOXO4-DRI?
PubMed indexes 19 papers mentioning FOXO4-DRI in the title or abstract, 14 of them from the last five years and 0 tagged as clinical trials (search run October 19, 2026; repeat the search).
Most relevant recent papers
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. — Nat Commun, 2025
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. — Circulation, 2023
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. — Commun Biol, 2025
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. — Exp Gerontol, 2024
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. — Front Bioeng Biotechnol, 2025
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. — Aging (Albany NY), 2020
What the evidence does not show
- Paper counts measure research attention, not whether FOXO4-DRI works or is safe.
- No clinical trial in humans is tagged in PubMed under this name.
- No FDA review of any "research use only" product's identity, purity, sterility or dose.
Research suppliers that list FOXO4-DRI
13 vendors in our directory listed a product matching FOXO4-DRI in their public catalog on October 19, 2026. Listed alphabetically; a listing is not an endorsement. Research use only.
- Atomik Labz
- BioLongevity Labs
- Biotech Peptides
- Core Peptides
- Ion Peptide
- Licensed Peptides
- NuScience Peptides
- Paramount Peptides
- Peptide Crafters
- Polaris Peptides
- Pure Lab Peptides
- Verified Peptides
- Xcel Peptides
Prices per mg, where we could verify them, are on our price comparison.
FOXO4-DRI reconstitution math
Lab arithmetic only, not dosing guidance: use the peptide calculator to turn a vial size and diluent volume into a concentration.
FOXO4-DRI FAQ
Is FOXO4-DRI FDA-approved?
FOXO4-DRI is not approved by the FDA for any use; products sold under this name are labeled for research use only, not for human consumption.
Is FOXO4-DRI safe?
There are no published human safety trials of FOXO4-DRI that we could find. Products sold as "research use only" have no FDA review of purity, sterility or dose, and are not for human use.
How much research is there on FOXO4-DRI?
PubMed indexes 19 papers on FOXO4-DRI (0 tagged as clinical trials) as of October 19, 2026.
Who sells FOXO4-DRI?
Atomik Labz, BioLongevity Labs, Biotech Peptides, Core Peptides, Ion Peptide, Licensed Peptides and 7 more listed it on their public catalogs when we checked; a listing is not an endorsement.
Related compounds
GlutathioneNAD+HumaninMOTS-cSS-31GLOW blendGHK-CuKLOW blendAll anti-aging & longevity